SCHEMBL5775365

SCHEMBL5775365

O=C(O)Cc1ccc(-n2nc3c4ccccc4[nH]cc-3c2=O)cc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SLC6A2 P23975 1/20 0.41
▸ FNTA P49354 1/20 0.41
▸ FNTB P49356 1/20 0.41
▸ LMNA P02545 2/20 0.41
▸ SIRT2 Q8IXJ6 1/20 0.39
▸ PTGER4 P35408 2/20 0.39
▸ MAPT P10636 2/20 0.39
▸ KMT2A Q03164 2/20 0.39
▸ KLK6 Q92876 1/20 0.39
▸ ALDH1A1 P00352 3/20 0.38
▸ CNR2 P34972 1/20 0.38
▸ PTGDR2 Q9Y5Y4 1/20 0.38
▸ NSD2 O96028 1/20 0.38
▸ POLB P06746 1/20 0.38
▸ GRK2 P25098 1/20 0.38
▸ CASP6 P55212 1/20 0.38
▸ CTDSP1 Q9GZU7 1/20 0.38
▸ SMN1; SMN2 Q16637 2/20 0.38
▸ KDM4E B2RXH2 1/20 0.38
▸ MEN1 O00255 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5774176 0.89 PPARD (0.44) SIRT2MAPTKMT2AALDH1A1CNR2
SCHEMBL1466280 0.85 ALDH1A1 (0.50) LMNASIRT2MAPTKMT2AALDH1A1
SCHEMBL29896410 0.85 ALDH1A1 (0.50) LMNASIRT2MAPTKMT2AALDH1A1
SCHEMBL5773359 0.85 HTT (0.53) MAPTKMT2AALDH1A1HPGDPDE10A
SCHEMBL7308745 0.83 AR (0.41) LMNASIRT2MAPTKMT2AALDH1A1
SCHEMBL7070603 0.82 ALDH1A1 (0.44) LMNAMAPTKMT2AKLK6ALDH1A1
SCHEMBL7308476 0.81 ALDH1A1 (0.43) ALDH1A1HPGDCYP2D6HTT
SCHEMBL5775440 0.81 KDM1A (0.45) MAPTKMT2AKLK6ALDH1A1SMN1; SMN2
SCHEMBL7308514 0.81 GAA (0.51) LMNAMAPTKMT2AALDH1A1POLB
SCHEMBL7306658 0.81 PDPK1 (0.42) LMNASIRT2MAPTKMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1409485-B1 IMMUNOMODULATING COMPOUNDS ACTIVE BIOTECH AB (SE) 2006-04-26 — — EP claimed
US-6642249-B2 3-Oxo-pyrazolo(4,3-c) -quinolin-2-yl, -thiochroman-2-yl, or -chromen-2-yl derivatives; CD80 antagonists ACTIVE BIOTECH AB (SE) 2003-11-04 — — US claimed
US-20030022913-A1 Novel immunomodulating compounds ACTIVE BIOTECH AB (SE) 2003-01-30 — — US claimed
EP-1409485-B1 IMMUNOMODULATING COMPOUNDS ACTIVE BIOTECH AB (SE) 2006-04-26 — — EP disclosed
US-6642249-B2 3-Oxo-pyrazolo(4,3-c) -quinolin-2-yl, -thiochroman-2-yl, or -chromen-2-yl derivatives; CD80 antagonists ACTIVE BIOTECH AB (SE) 2003-11-04 — — US disclosed
US-20030022913-A1 Novel immunomodulating compounds ACTIVE BIOTECH AB (SE) 2003-01-30 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030022913-A1 Novel immunomodulating compounds CD40, ICOS, CD40LG SLC6A2 2907/4885FNTA 2331/4885FNTB 2779/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback